IDEXX Laboratories, Inc. $IDXX Shares Sold by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 38,918 shares of the company’s stock after selling 804 shares during the period. IDEXX Laboratories comprises 2.3% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 12th biggest position. Marble Harbor Investment Counsel LLC’s holdings in IDEXX Laboratories were worth $20,873,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Opal Wealth Advisors LLC acquired a new position in IDEXX Laboratories in the second quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after purchasing an additional 30 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $36,000. WPG Advisers LLC purchased a new stake in IDEXX Laboratories during the first quarter worth $37,000. Finally, Bank of Jackson Hole Trust grew its position in IDEXX Laboratories by 328.6% during the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after buying an additional 69 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on IDXX shares. Wall Street Zen upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday. JPMorgan Chase & Co. increased their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research report on Monday, November 3rd. Piper Sandler reiterated a “neutral” rating and set a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $730.50.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $712.47 on Wednesday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The stock has a market cap of $56.89 billion, a P/E ratio of 59.32, a PEG ratio of 4.06 and a beta of 1.62. The company has a 50-day moving average price of $647.99 and a 200 day moving average price of $584.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.40 EPS for the quarter, beating the consensus estimate of $3.14 by $0.26. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the company earned $2.80 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director owned 262 shares of the company’s stock, valued at approximately $169,600.46. This represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.